10 Muharram 1446 - 16 July 2024
Sign up for newsletter
Eye of Riyadh
Healthcare | Thursday 11 January, 2024 10:08 am |

Abu Dhabi Stem Cells Center Partners with Japan-based Kyoto University and Rege Nephro

Abu Dhabi Stem Cells Center (ADSCC) has announced today a


groundbreaking joint research agreement with one of Japan and Asia's top research institutions,


Kyoto University - Center for iPS Cell Research and Application (CiRA), and Rege Nephro, a Japan-


based biotech company that specializes in R&D and production of renal disease therapeutics.


The collaboration is poised to revolutionise diabetes care by developing a new innovative treatment


using pancreatic beta cells derived from human induced pluripotent stem cells (iPS cells). iPS cells


are obtained from skin or blood cells and are then reprogrammed (genetically modified) in highly


advanced laboratories to create cells that replicate the tissue affected by diabetes. To facilitate this


joint revolutionary research mission, an ADSCC laboratory was launched at the premises of Kyoto


University in Japan.


The joint research will focus on developing iPS cell-derived pancreatic beta cells with enhanced


therapeutic efficacy through genetic modifications, offering cell therapy options for patients with


type 1 diabetes in addition to screening and testing potential drugs for type 2 diabetes to develop


novel approaches for managing type 2 diabetes.


Prof. Dr Yendry Ventura, CEO of ADSCC, Adjunct Professor at UAE University, and Research Scientist


said: “The robust collaboration between the UAE and Japan transcends borders and languages, manifesting in a shared dedication to advancing healthcare. This partnership serves as an ideal


example of international cooperation, where our combined efforts propel us closer to achieving


excellence in diabetes care for our respective populations and beyond. At ADSCC, we are on a


mission to make a profound impact in the field of diabetes care and cellular therapy globally, and in


pursuit of this ambitious journey, we have consciously embarked on this strategic partnership with CiRA and Rege Nephro.”


Professor Kenji Osafune, Head of the Department of Cell Growth and Differentiation at the Center


for iPS Cell Research and Application (CiRA) at Kyoto University and Founder of Rege Nephro, said: ”Partnering with ADSCC in this joint research will not only enable us to apply the foundational technology developed in research across the Middle East and North Africa but also establish a


pivotal hub for advancing regenerative medicine research through iPS cell technology in the region.


CiRA and Rege Nephro share a common mission with ADSCC to provide swift and effective treatments for diabetes, ultimately enhancing the quality of life and prognosis for patients worldwide.”


Prof. Dr Ventura added, “In alignment with the vision of the UAE’s leadership, ADSCC is honoured to spearhead this international collaboration, bringing cutting-edge regenerative medicine and cellular therapies to the Middle East and North Africa. With the Department of Health - Abu Dhabi support in innovation and research, we believe this partnership will pave the way for transformative healthcare


solutions in our region and beyond. We are also proud to have launched our ADSCC laboratory at Kyoto University premises to facilitate our mission.”


The importance of this collaboration lies in addressing the significant global burden of diabetes,


characterized by pancreatic beta cell dysfunction, which affects 537 million individuals worldwide. Its


complications, including chronic kidney disease, cerebral infarction, and myocardial infarction, pose


substantial health risks. The prevalence of diabetes in the UAE was reported by the International


Diabetes Federation (IDF) to be 16.3%. Research shows that diabetes has the highest regional


prevalence in the Middle East and North Africa.


Post Your Comment